Swedish clinical-stage pharmaceutical company Vicore Pharma Holding AB (STO:VICO) announced on Friday an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku Co Ltd, granting rights for the development and commercialisation of Vicore's drug candidate C21 in Japan.
Vicore will receive an upfront payment of USD10m and stands to gain up to USD275m in milestone payments, along with tiered royalty payments.
Nippon Shinyaku will initially focus on developing C21 for idiopathic pulmonary fibrosis (IPF), aiming to address the limited treatment options for approximately 34,000 patients in Japan.
Vicore retains all rights to C21 outside of Japan.
C21, an oral therapy, has shown promising results in stabilising or improving lung function in IPF patients. A global Phase 2b ASPIRE study is planned to begin in the first half of this year.
Regeneron and Sanofi's Dupixent gains EU approval for uncontrolled COPD with eosinophilia
INOVIO names new chief commercial officer
Carisma Therapeutics names new directors
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
Biophytis signs Latin American deal with Blanver for BIO101 (20-Hydroxyecdysone)
Natera unveils enhanced Prospera Heart test for transplant patients
Biophytis reports industrial scale production of DMD drug candidate BIO101
EMA grants orphan drug designation to Moleculin's Annamycin for AML
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
ProAxsis secures GBP1.8m investment
CareDx highlights cardiothoracic advancements at ISHLT meeting